急性冠脉综合征后转换双联抗血小板治疗的获益:TOPIC随机研究
主要终点为1年时心血管死亡、紧急血运重建、卒中及BARC≥2级出血的复合终点,转换组43例(13.4%)vs 未转换组85例(26.3%)(HR 0.48,95%CI 0.34-0.68,P<0.01)。结论认为转换DAPT在预防出血并发症方面优于未转换DAPT,且不增加缺血事件。
要点
- ACS后1个月无事件患者转换为阿司匹林加氯吡格雷可降低出血风险。
- 转换DAPT组主要复合终点发生率13.4%,未转换组26.3%,HR 0.48。
- BARC≥2级出血转换组4.0% vs 未转换组14.9%,HR 0.30,缺血终点无显著差异。
核心结论
- ACS后转换DAPT(阿司匹林加氯吡格雷)在预防出血并发症方面优于未转换DAPT(阿司匹林加新型P2Y12阻滞剂),且不增加缺血事件。
研究设计与样本
- 开放标签、单中心、随机试验,2014年3月至2016年4月纳入ACS接受冠脉介入、服用阿司匹林加新型P2Y12阻滞剂且1个月时无不良事件的患者,随机分为转换DAPT组(阿司匹林加氯吡格雷)或未转换DAPT组(继续原方案)。
主要发现
- 主要终点(心血管死亡、紧急血运重建、卒中及BARC≥2级出血的复合终点)在转换DAPT组发生43例(13.4%),未转换DAPT组发生85例(26.3%),HR 0.48(95%CI 0.34-0.68),P<0.01。
- BARC≥2级出血在转换DAPT组发生13例(4.0%),未转换DAPT组发生48例(14.9%),HR 0.30(95%CI 0.18-0.50),P<0.01。
- 缺血终点无显著差异。
关键数值与推荐
- 主要终点:1年时心血管死亡、紧急血运重建、卒中及BARC≥2级出血的复合终点。
- 转换DAPT组主要终点43例(13.4%)vs 未转换DAPT组85例(26.3%),HR 0.48(95%CI 0.34-0.68),P<0.01。
- BARC≥2级出血转换DAPT组13例(4.0%)vs 未转换DAPT组48例(14.9%),HR 0.30(95%CI 0.18-0.50),P<0.01。
临床怎么用
- ACS后1个月无不良事件且正在服用阿司匹林加新型P2Y12阻滞剂的患者,可考虑转换为阿司匹林加氯吡格雷以降低出血风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant ischaemic benefit over clopidogrel after acute coronary syndrome (ACS). However, both drugs are associated with an increase in bleeding complications. The objective of the present study was to evaluate the benefit of switching dual antiplatelet therapy (DAPT) from aspirin plus a newer P2Y12 blocker to aspirin plus clopidogrel 1 month after ACS. METHODS AND RESULTS: We performed an open-label, monocentric, and randomized trial. From March 2014 to April 2016, patients admitted with ACS requiring coronary intervention, on aspirin and a newer P2Y12 blocker and without adverse event at 1 month, were assigned to switch to aspirin and clopidogrel (switched DAPT) or continuation of their drug regimen (unchanged DAPT). The primary outcome was a composite of cardiovascular death, urgent revascularization, stroke and bleeding as defined by the Bleeding Academic Research Consortium (BARC) classification ≥2 at 1 year post ACS. Six hundred and forty six patients were randomized and 645 analysed, corresponding to 322 patients in the switched DAPT and 323 in the unchanged DAPT group. The primary endpoint occurred in 43 (13.4%) patients in the switched DAPT group and in 85 (26.3%) patients in the unchanged DAPT (HR 95%CI 0.48 (0.34-0.68), P < 0.01). No significant differences were reported on ischaemic endpoints, while BARC ≥ 2 bleeding occurred in 13 (4.0%) patients in the switched DAPT and in 48 (14.9%) in the unchanged DAPT group (HR 95%CI 0.30 (0.18-0.50), P < 0.01). CONCLUSION: A switched DAPT is superior to an unchanged DAPT strategy to prevent bleeding complications without increase in ischaemic events following ACS.
引用
- Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017. PMID: 28510646. doi:10.1093/eurheartj/ehx175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。